Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pharmacology ; 106(1-2): 114-118, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-32950991

RESUMO

Obsessive compulsive disorder (OCD) is a psychiatric disorder characterized by excessive and repetitive thoughts and gestures, mainly treated pharmacologically with selective serotonin reuptake inhibitors (SSRIs). The marble burying test in mice is commonly used to model OCD and has been shown to be sensitive to SSRIs, which decrease burying behavior. The activity of SSRIs in this model is mediated through activation of 5-hydroxytryptamine (5-HT) 1A receptors, but the respective implication of pre- versus postsynaptic 5-HT1A receptors has not been elucidated. Here, we investigated marble burying behavior by male NMRI mice following acute administration of 3 biased agonists, which preferentially activate presynaptic 5-HT1A receptors (F13714) or postsynaptic receptors (NLX-101) or which exhibit balanced activation of both pre- and postsynaptic 5-HT1A receptors (NLX-112). When administered at the dose of 2.5 mg/kg i.p., all 3 biased agonists completely or nearly completely abolished marble burying behavior. However, they varied in their potency with minimal effective doses of 0.16, 0.63, and 2.5 mg/kg i.p., for F13714, NLX-112, and NLX-101, respectively. The selective 5-HT1A receptor antagonist, WAY100,635 was inactive up to 2.5 mg/kg. These results suggest that marble burying behavior in male NMRI mice is preferentially sensitive to activation of pre- versus postsynaptic 5-HT1A receptors. Moreover, they suggest that targeting 5-HT1A receptors with biased agonists could provide an innovative therapeutic approach to combat OCD.


Assuntos
Comportamento Animal/efeitos dos fármacos , Receptor 5-HT1A de Serotonina/efeitos dos fármacos , Receptores Pré-Sinápticos/efeitos dos fármacos , Agonistas do Receptor 5-HT1 de Serotonina/administração & dosagem , Agonistas do Receptor 5-HT1 de Serotonina/farmacologia , Aminopiridinas/administração & dosagem , Aminopiridinas/farmacologia , Animais , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Injeções Intraperitoneais , Masculino , Camundongos Endogâmicos , Transtorno Obsessivo-Compulsivo/tratamento farmacológico , Piperazinas/administração & dosagem , Piperazinas/farmacologia , Piperidinas/administração & dosagem , Piperidinas/farmacologia , Piridinas/administração & dosagem , Piridinas/farmacologia , Pirimidinas/administração & dosagem , Pirimidinas/farmacologia , Antagonistas da Serotonina/administração & dosagem , Antagonistas da Serotonina/farmacologia , Sinapses/efeitos dos fármacos
2.
Eur J Pharmacol ; 890: 173635, 2021 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-33065094

RESUMO

F17464 (N-(3-{4-[4-(8-Oxo-8H-[1,3]-dioxolo-[4,5-g]-chromen-7-yl)-butyl]-piperazin-1-yl}-phenyl)-methanesulfonamide, hydrochloride) is a new potential antipsychotic with a unique profile. The compound exhibits high affinity for the human dopamine receptor subtype 3 (hD3) (Ki = 0.17 nM) and the serotonin receptor subtype 1a (5-HT1a) (Ki = 0.16 nM) and a >50 fold lower affinity for the human dopamine receptor subtype 2 short and long form (hD2s/l) (Ki = 8.9 and 12.1 nM, respectively). [14C]F17464 dynamic studies show a slower dissociation rate from hD3 receptor (t1/2 = 110 min) than from hD2s receptor (t1/2 = 1.4 min) and functional studies demonstrate that F17464 is a D3 receptor antagonist, 5-HT1a receptor partial agonist. In human dopaminergic neurons F17464 blocks ketamine induced morphological changes, an effect D3 receptor mediated. In vivo F17464 target engagement of both D2 and 5-HT1a receptors is demonstrated in displacement studies in the mouse brain. F17464 increases dopamine release in the rat prefrontal cortex and mouse lateral forebrain - dorsal striatum and seems to reduce the effect of MK801 on % c-fos mRNA medium expressing neurons in cortical and subcortical regions. F17464 also rescues valproate induced impairment in a rat social interaction model of autism. All the neurochemistry and behavioural effects of F17464 are observed in the dose range 0.32-2.5 mg/kg i.p. in both rats and mice. The in vitro - in vivo pharmacology profile of F17464 in preclinical models is discussed in support of a therapeutic use of the compound in schizophrenia and autism.


Assuntos
Antipsicóticos/farmacologia , Benzopiranos/farmacologia , Antagonistas de Dopamina/farmacologia , Piperazinas/farmacologia , Receptores de Dopamina D3/antagonistas & inibidores , Sulfonamidas/farmacologia , Animais , Antipsicóticos/uso terapêutico , Transtorno Autístico/induzido quimicamente , Transtorno Autístico/tratamento farmacológico , Comportamento Animal/efeitos dos fármacos , Benzopiranos/uso terapêutico , Monoaminas Biogênicas/metabolismo , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Catalepsia/tratamento farmacológico , Células Cultivadas , Dopamina/metabolismo , Antagonistas de Dopamina/uso terapêutico , Neurônios Dopaminérgicos/efeitos dos fármacos , Feminino , Genes fos/efeitos dos fármacos , Masculino , Camundongos , Plasticidade Neuronal/efeitos dos fármacos , Piperazinas/uso terapêutico , Prolactina/sangue , Ratos Sprague-Dawley , Receptores de Dopamina D3/metabolismo , Sulfonamidas/uso terapêutico , Ácido Valproico/toxicidade
3.
J Neurochem ; 114(5): 1323-32, 2010 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-20534001

RESUMO

The function of the serotonin(2B) receptor (5-HT(2B)R) in the mammalian brain is poorly characterized, especially with regard to its influence on dopamine (DA) neuron activity. Here, we assessed this issue by evaluating effects of 5-HT(2B)Rs ligands in the control of striatal and accumbal DA outflow, using in vivo microdialysis in halothane-anesthetized rats, and amphetamine-induced hyperlocomotion in vigil rats. The selective 5-HT(2B)R antagonist 1-[(2-chloro-3,4-dimethoxyphenyl)methyl]-2,3,4,9-tetrahydro-6-methyl-1H-pyrido[3,4-B]indole (LY 266097; 0.16 mg/kg, i.p.) had no influence on basal accumbal and striatal DA outflow but reduced significantly accumbal DA outflow when injected at 0.63 mg/kg. A significant reduction of basal DA outflow in the nucleus accumbens was also observed after i.p. administration of 0.16 mg/kg 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine, another selective 5-HT(2B)R antagonist. In contrast, the 5-HT(2B)R agonist alpha-methyl-5-(2-thienylmethoxy)-1H-indole-3-ethanamine (3 mg/kg, s.c.) had no influence on basal DA outflow in either brain region. The increase in striatal and accumbal DA outflow induced by the 5-HT(2C)R inverse agonist 5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f] indole (5 mg/kg, i.p.) was unaltered by LY 266097 (0.63 mg/kg) pre-treatment. Conversely, LY 266097 (0.63 mg/kg) significantly diminished the increase in DA outflow induced by haloperidol (0.01 mg/kg, s.c.) or amphetamine (0.5 mg/kg, i.p.) in the nucleus accumbens, but not in the striatum. Amphetamine-induced hyperlocomotion (1 mg/kg) was also attenuated by LY 266097 (0.63 mg/kg). These findings demonstrate that 5-HT(2B)Rs exert a facilitatory control on mesoaccumbens DA pathway activity, and suggest that they may constitute a new target for improved treatment of DA-related neuropsychiatric disorders.


Assuntos
Dopamina/fisiologia , Sistemas de Liberação de Medicamentos/tendências , Núcleo Accumbens/fisiologia , Receptor 5-HT2B de Serotonina/fisiologia , Transdução de Sinais/fisiologia , Animais , Dopamina/metabolismo , Masculino , Atividade Motora/efeitos dos fármacos , Atividade Motora/fisiologia , Núcleo Accumbens/efeitos dos fármacos , Núcleo Accumbens/patologia , Ratos , Ratos Sprague-Dawley , Antagonistas do Receptor 5-HT2 de Serotonina , Antagonistas da Serotonina/administração & dosagem , Transdução de Sinais/efeitos dos fármacos
4.
Eur Neuropsychopharmacol ; 20(9): 641-54, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20488670

RESUMO

We assessed the activity of F15599, a selective and high efficacy 5-HT(1A) agonist that preferentially activates post- versus pre-synaptic receptors, in rat cognition/memory models. F15599 (0.16 mg/kg i.p.) partially alleviated detrimental effects of phencyclidine on working and reference memory deficit in a hole-board model. It also attenuated phencyclidine-induced deficit of cognitive flexibility in a reversal learning task, without effects of its own. F13714 (0.04 mg/kg) a chemical congener of F15599, and 8-OH-DPAT (0.01 or 0.16), were inactive against these phencyclidine-induced deficits, and/or even worsened basal performances. F15599 (0.04-2.5) was less disruptive than F13714 (0.005-0.16) or 8-OH-DPAT (0.01-0.63), on basal performance in models of attention (5-choice serial reaction time task) and working memory (delayed non-matching to position). Finally, unlike either comparator, F15599 reduced PPI with modest potency and only partially. To conclude, F15599, in models of memory/cognition, has a more favourable profile than F13714 and 8-OH-DPAT. This suggests that preferential activation of post-synaptic 5-HT(1A) receptors could prove useful in pathologies characterized by cognitive/memory deficiencies, such as schizophrenia and depression.


Assuntos
Cognição/efeitos dos fármacos , Piperidinas/farmacologia , Pirimidinas/farmacologia , Receptor 5-HT1A de Serotonina/metabolismo , Agonistas do Receptor 5-HT1 de Serotonina/farmacologia , 8-Hidroxi-2-(di-n-propilamino)tetralina/metabolismo , 8-Hidroxi-2-(di-n-propilamino)tetralina/farmacologia , Aminopiridinas/metabolismo , Aminopiridinas/farmacologia , Animais , Modelos Animais de Doenças , Inibidores Enzimáticos/farmacologia , Masculino , Memória de Curto Prazo/efeitos dos fármacos , Fenciclidina/farmacologia , Piperidinas/metabolismo , Ratos , Ratos Sprague-Dawley , Reflexo de Sobressalto/efeitos dos fármacos , Transdução de Sinais
5.
Int J Neuropsychopharmacol ; 13(10): 1285-98, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20059805

RESUMO

F15599 is a novel agonist with high selectivity and efficacy at serotonin 5-HT(1A) receptors (5-HT(1A)Rs). In signal transduction, electrophysiological and neurochemical tests, F15599 preferentially activates post-synaptic 5-HT(1A)Rs in rat frontal cortex. Such a profile may translate to an improved profile of therapeutic activity for mood disorders. The in-vivo effects of F15599 were therefore compared with those of a related compound, F13714, in rat models of antidepressant activity and 5-HT(1A)R activation: forced swimming test (FST), conditioned stress-induced ultrasonic vocalization, 5-HT syndrome, plasma corticosterone and body temperature. Acute administration of F15599 or F13714 reduced immobility in the FST at low doses; these effects were long lasting and the effects of F15599 were maintained after repeated (5 d, p.o.) administration. Both compounds decreased ultrasonic vocalization duration at low doses. In contrast, higher doses of F15599 were required to induce lower lip retraction, elements of the 5-HT behavioural syndrome, hypothermia and to increase plasma corticosterone levels. Notably, there was a greater separation of ED50 between FST and other effects for F15599 than for F13714. Thus, the in-vivo potency of F15599 in models of antidepressant/anti-stress activity is similar to that of F13714, despite the fact that the latter has an in-vitro potency two orders of magnitude greater. In contrast F15599 has a lower propensity than F13714 to induce other serotonergic signs. The distinctive pharmacological profile of F15599 suggests that preferential targeting of post-synaptic 5-HT(1A)Rs constitutes a promising strategy for improved antidepressant therapy.


Assuntos
Aminopiridinas/farmacologia , Antidepressivos/farmacologia , Depressão/tratamento farmacológico , Terapia de Alvo Molecular , Piperidinas/farmacologia , Agonistas do Receptor 5-HT1 de Serotonina/uso terapêutico , Animais , Corticosterona/sangue , Corticosterona/metabolismo , Hipotermia/induzido quimicamente , Masculino , Modelos Animais , Atividade Motora/efeitos dos fármacos , Piperidinas/uso terapêutico , Córtex Pré-Frontal/efeitos dos fármacos , Pirimidinas/uso terapêutico , Ratos , Ratos Sprague-Dawley , Ratos Wistar , Serotonina/farmacologia , Estresse Fisiológico/efeitos dos fármacos , Natação/fisiologia
6.
Behav Brain Res ; 203(2): 288-95, 2009 Nov 05.
Artigo em Inglês | MEDLINE | ID: mdl-19464324

RESUMO

Typical antipsychotics such as haloperidol exert their therapeutic effects via blockade of dopamine (DA) D(2) receptors, leading to extrapyramidal symptoms (EPS) in humans and catalepsy in rodents. In contrast, atypical antipsychotics and new generation D(2)/5-HT(1A) antipsychotics have low cataleptogenic potential. However, there has been no systematic comparative study on the effects of these different classes of antipsychotics in non-human primates, a species displaying a more sophisticated repertoire of behavioural/motor activity than rats. Once weekly, six young adult female non-haloperidol-sensitised cynomolgus monkeys were treated i.m. with a test compound and videotaped to score catalepsy-associated behaviour (CAB: static postures, unusual positions and crouching). Haloperidol, risperidone, olanzapine, nemonapride and remoxipride induced, to different extents, an increase in unusual positions (a response akin to dystonia), some crouching and static postures. In contrast, clozapine, quetiapine, ziprasidone and aripiprazole produced much lower or no unusual positions; clozapine also produced marked increases in static postures and crouching. Among novel D(2)/5-HT(1A) antipsychotics, SLV313 and F15063 augmented the number of unusual positions, albeit at doses 16-63 times higher than those of haloperidol for approximately the same score. SSR181507 and bifeprunox produced moderate static postures, little crouching and negligible unusual positions. These data provide the first comparative analysis in cynomolgus monkeys of EPS liability of conventional, atypical and novel D(2)/5-HT(1A) antipsychotics. They indicate that the latter are less prone than haloperidol to produce CAB, and provide a basis for comparison with rodent catalepsy studies.


Assuntos
Antipsicóticos/efeitos adversos , Catalepsia/induzido quimicamente , Antagonistas de Dopamina/efeitos adversos , Agonistas do Receptor de Serotonina/efeitos adversos , 8-Hidroxi-2-(di-n-propilamino)tetralina/efeitos adversos , Animais , Aripiprazol , Benzamidas/efeitos adversos , Benzodiazepinas/efeitos adversos , Benzoxazóis/efeitos adversos , Clozapina/efeitos adversos , Dibenzotiazepinas/efeitos adversos , Dioxanos/efeitos adversos , Feminino , Haloperidol/efeitos adversos , Macaca fascicularis , Olanzapina , Piperazinas/efeitos adversos , Fumarato de Quetiapina , Quinolonas/efeitos adversos , Remoxiprida/efeitos adversos , Risperidona/efeitos adversos , Tiazóis/efeitos adversos , Tropanos/efeitos adversos , Gravação em Vídeo
7.
Pharmacol Biochem Behav ; 92(2): 363-9, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19353758

RESUMO

The 5-choice serial reaction time task (5-CSRTT) allows examination of multiple aspects of cognition/executive functions (attention/impulsivity/ perseveration). Most 5-CSRTT studies are performed with pigmented (i.e. Long-Evans: LE) rats; however, albino strains (i.e. Sprague-Dawley: SD) are more commonly used in behavioural pharmacology experiments. Hence, we compared 5-CSRTT performances of SD and LE rats and their sensitivity to acute phencyclidine (PCP, 1-2.5 mg/kg). SD required significantly fewer sessions(35 versus 50) than LE rats for task acquisition, especially at shortest stimulus light duration (1 s). However,once trained, under vehicle conditions, both strains performed similarly. In contrast, PCP treatment differentially affected the two strains. Thus, whilst percentage of accuracy was decreased for both strains, in SD rats number of premature responses was more markedly decreased, whereas omissions and latency time to correct responses were more notably increased. In addition, PCP monotonically diminished in SD, but augmented (1-1.5 mg/kg) in LE rats compulsive responding. To summarize, under our experimental conditions, the SD offer advantages over LE strain for speed of acquisition of 5-CSRTT. Once trained, basal performances of both strains were equivalent and stable enough for challenge with pharmacological compounds. However, PCP differentially affected the strains on several parameters considered.


Assuntos
Fenciclidina/farmacologia , Tempo de Reação , Animais , Ratos , Ratos Long-Evans , Ratos Sprague-Dawley
8.
Behav Pharmacol ; 19(2): 145-52, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18332679

RESUMO

Antipsychotics constitute efficacious augmenting agents in the treatment of anxiety disorders, including refractory obsessive-compulsive disorder. We examined the effects of 36 compounds, including typical, atypical and novel antipsychotics with dual dopamine D2/5-hydroxytryptamine 1A (D2/5-HT1A) actions on marble burying behavior in mice, a putative preclinical test for anxiety disorders. One hour after drug administration, male NMRI mice were placed individually in cages containing 20 marbles, and the total number of marbles buried after 30 min was counted. The selective serotonin reuptake inhibitors, citalopram (2.5-40 mg/kg), fluoxetine (2.5-10 mg/kg) and the benzodiazepine diazepam (2.5-10 mg/kg), reduced the number of buried marbles. The atypical antipsychotic, clozapine (0.16-10 mg/kg), but not its congener olanzapine, was effective in this test. Haloperidol, a typical antipsychotic, also reduced the number of buried marbles, albeit not in a dose-dependent manner. The atypical risperidone was partially active (0.16-0.63 mg/kg), as was the benzamide derivative, amisulpride, albeit at high (10-40 mg/kg) doses. Among the 'third-generation' antipsychotics possessing combined D2/5-HT1A properties, bifeprunox was active at 0.0025 mg/kg, whereas SLV313 and aripiprazole were active only at the highest doses (2.5 and 10 mg/kg, respectively). SSR181507, F15063 and the antidyskinetic agent, sarizotan, were without any effect. Among a series of receptor subtype-selective ligands, only the 5-HT1A agonist, (+)-8-OH-DPAT (0.63-2.5 mg/kg) and the 5-HT2A/2B/2C antagonist, ritanserin (0.63-2.5 mg/kg) were active. Among novel antipsychotics with dual D2/5-HT1A properties, only bifeprunox was able to potently reduce the number of buried marbles. Inhibition of marble burying behavior may result from the interplay of several receptor systems, including 5-HT2 receptor blockade, dopamine D2 partial agonism and serotonin 5-HT1A agonism.


Assuntos
Antipsicóticos/farmacologia , Nível de Alerta/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Atividade Motora/efeitos dos fármacos , Receptor 5-HT1A de Serotonina/efeitos dos fármacos , Receptores de Dopamina D2/efeitos dos fármacos , Comportamento Estereotipado/efeitos dos fármacos , Animais , Relação Dose-Resposta a Droga , Masculino , Camundongos , Relação Estrutura-Atividade
9.
Psychopharmacology (Berl) ; 193(1): 45-54, 2007 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17393144

RESUMO

INTRODUCTION: Prepulse inhibition (PPI) of the startle reflex has been extensively studied because it is disrupted in several psychiatric diseases, most notably schizophrenia. In rats, and to a lesser extent, in humans, PPI can be diminished by dopamine (DA) D(2)/D(3) and serotonin 5-HT(1A) receptor agonists. A novel class of potential antipsychotics (SSR181507, bifeprunox, and SLV313) possess partial agonist/antagonist properties at D(2) receptors and various levels of 5-HT(1A) activation. MATERIALS AND METHODS: It thus appeared warranted to assess, in Sprague-Dawley rats, the effects of these antipsychotics on basal PPI. RESULTS: SSR181507, sarizotan, and bifeprunox decreased PPI, with a near-complete abolition at 2.5-10 mg/kg; SLV313 had a significant effect at 0.16 mg/kg only. Co-treatment with the 5-HT(1A) receptor antagonist WAY100,635 (0.63 mg/kg) showed that the 5-HT(1A) agonist activity of SSR181507 was responsible for its effect. By contrast, antipsychotics with low affinity and/or efficacy at 5-HT(1A) receptors, such as aripiprazole (another DA D(2)/D(3) and 5-HT(1A) ligand), and established typical and atypical antipsychotics (haloperidol, clozapine, risperidone, olanzapine, quetiapine, and ziprasidone) had no effect on basal PPI (0.01-2.5 to 2.5-40 mg/kg). DISCUSSION: The present data demonstrate that some putative antipsychotics with pronounced 5-HT(1A) agonist activity, coupled with partial agonist activity at DA D(2) receptors, markedly diminish PPI of the startle reflex in rats. CONCLUSIONS: These data raise the issue of the influence of such compounds on sensorimotor gating in humans.


Assuntos
Antipsicóticos/farmacologia , Receptores de Dopamina D2/agonistas , Reflexo de Sobressalto/efeitos dos fármacos , Agonistas do Receptor 5-HT1 de Serotonina , Animais , Antagonistas dos Receptores de Dopamina D2 , Relação Dose-Resposta a Droga , Masculino , Ratos , Ratos Sprague-Dawley
10.
Neuropsychopharmacology ; 31(9): 1900-9, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16421514

RESUMO

The dopamine D1/D2 agonist apomorphine (0.63 mg/kg) disrupted prepulse inhibition (PPI) of acoustic startle in rats, a model of sensorimotor gating deficits observed in schizophrenia. All current antipsychotics, which antagonize D2 receptors, prevent this apomorphine-induced deficit. A novel class of antipsychotics possesses, in addition to D2 antagonist property, various levels of 5-HT1A agonist activity. Considering that the latter itself produces PPI deficits, it appeared necessary to assess the potential of this novel class of antipsychotics to reverse apomorphine-PPI deficits. Potent D2 antagonists, like haloperidol (0.63-2.5 mg/kg), risperidone (0.63-10 mg/kg), and olanzapine (0.63-40 mg/kg) prevented apomorphine PPI disruption. The atypical antipsychotics, clozapine (40 mg/kg), nemonapride (0.01-2.5 mg/kg), ziprasidone (10 mg/kg), and aripiprazole (0.01 and 10 mg/kg), which all exhibit 5-HT1A agonist properties, reversed PPI deficits at some doses only, whereas the anti-dyskinetic agent sarizotan (0.16-10 mg/kg), an efficacious 5-HT1A agonist, did not. New generation antipsychotics with marked 5-HT1A agonist properties, such as SLV313 and SSR181507 (0.0025-10 mg/kg and 0.16-10 mg/kg, respectively) did not reverse these deficits whereas bifeprunox (0.04-2.5 mg/kg) did. To reveal the contribution of 5-HT1A agonist properties in the lack of effects of SLV313 and SSR181507, we pretreated rats with the 5-HT1A antagonist WAY100635 (0.63 mg/kg). Under these conditions, significant reversal of PPI deficit was observed, indicating that D2 antagonist properties of SLV313 and SSR181507 are now sufficient to overcome the disruptive effects of apomorphine. To summarize, antipsychotics possessing agonist efficacy at 5-HT1A receptors exhibit diverse profiles against apomorphine-induced PPI deficits, depending on the balance between D2 and 5-HT1A activities, suggesting that they may display distinct activity on some aspects of gating deficits in schizophrenic patients.


Assuntos
Antipsicóticos/farmacologia , Apomorfina/antagonistas & inibidores , Apomorfina/farmacologia , Agonistas de Dopamina/farmacologia , Antagonistas de Dopamina/farmacologia , Antagonistas dos Receptores de Dopamina D2 , Agonistas do Receptor 5-HT1 de Serotonina , Agonistas do Receptor de Serotonina/farmacologia , Aminopiridinas/farmacologia , Animais , Dioxanos/farmacologia , Relação Dose-Resposta a Droga , Masculino , Piperazinas/farmacologia , Piperidinas/farmacologia , Piridinas/farmacologia , Ratos , Ratos Sprague-Dawley , Antagonistas da Serotonina/farmacologia , Tropanos/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...